Mostafa Abd Alfattah Shamkh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mostafa Abd Alfattah Shamkh has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Ahmed Fouad Sherief
Inflammatory bowel disease unit, Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
1 shared publicationAhmed Sherief
Department of Tropical Medicine, Faculty of Medicine, Ain Shams University Abbasia square, Cairo, Egypt
1 shared publication- Amira Mahmoud Al Balakosy
Ain Shams University, Cairo, Egypt
1 shared publication Azza Hassan
Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Abbasia Square, Cairo, Egypt
1 shared publicationEthar Badran
Department of Tropical Medicine, Faculty of Medicine, Ain Shams University Abbasia square, Cairo, Egypt
1 shared publicationHany Dabbous
Department of Tropical Medicine, Faculty of Medicine, Ain Shams University Abbasia square, Cairo, Egypt
1 shared publication
Latest Publications
- Open Access
- 19 February 2022
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 34 (1) , 1-10
A decade of inflammatory bowel disease: a single center experience in Egypt
Background: Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract and includes ulcerative colitis and Crohn’s disease. Inflammatory bowel disease has always seemed to be rare in the Middle East and Northern Africa. In this study, we explored the clinical characteristics of inflammatory bowel disease patients in our center. Methods: This retrospective study was conducted on patients with an established diagnosis of inflammatory bowel disease over 10 years from September 2009 to September 2019 who were referred to our inflammatory bowel disease center. Clinical information was obtained from medical records and patient interviews. We included all patients in whom the diagnosis of ulcerative colitis or Crohn’s disease was confirmed by clinical, laboratory, endoscopic, and histological examination over a 10-year period from 2009 to 2019. Results: Our study had one hundred and sixty-nine inflammatory bowel disease patients; one hundred and thirty-six ulcerative colitis patients and the remaining thirty-three patients had Crohn’s disease. The main presenting symptom was bloody diarrhea (78 patients) representing 46.2% of the patients in our study. The majority of ulcerative colitis patients (55.9%) had moderate disease (Truelove & Witts score), while the majority of Crohn’s disease patients (66.7%) had moderate to severe disease (Crohn’s Disease Activity Index). Conclusions: The prevalence of inflammatory bowel disease is still low in Egypt despite the rising curve of newly diagnosed cases.
- 19 February 2022
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 34 (1) , 1-10
Open AccessA decade of inflammatory bowel disease: a single center experience in Egypt
Background: Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract and includes ulcerative colitis and Crohn’s disease. Inflammatory bowel disease has always seemed to be rare in the Middle East and Northern Africa. In this study, we explored the clinical characteristics of inflammatory bowel disease patients in our center. Methods: This retrospective study was conducted on patients with an established diagnosis of inflammatory bowel disease over 10 years from September 2009 to September 2019 who were referred to our inflammatory bowel disease center. Clinical information was obtained from medical records and patient interviews. We included all patients in whom the diagnosis of ulcerative colitis or Crohn’s disease was confirmed by clinical, laboratory, endoscopic, and histological examination over a 10-year period from 2009 to 2019. Results: Our study had one hundred and sixty-nine inflammatory bowel disease patients; one hundred and thirty-six ulcerative colitis patients and the remaining thirty-three patients had Crohn’s disease. The main presenting symptom was bloody diarrhea (78 patients) representing 46.2% of the patients in our study. The majority of ulcerative colitis patients (55.9%) had moderate disease (Truelove & Witts score), while the majority of Crohn’s disease patients (66.7%) had moderate to severe disease (Crohn’s Disease Activity Index). Conclusions: The prevalence of inflammatory bowel disease is still low in Egypt despite the rising curve of newly diagnosed cases.
- 25 August 2021
- Published by Egyptian Knowledge Bank in Afro-Egyptian Journal of Infectious and Endemic Diseases
- Vol. 11 (3) , 306-313
Measles IgG Antibodies: Is There a Protective Role in COVID 19 Pandemic?
Background and study aim: Epidemiological data reported lower death rates of COVID-19 cases in countries with higher & recent coverage by measles containing vaccines. In this study we aim to identify measles IgG titer in COVID-19 patients & correlate it with disease severity. Patients and Method: This is a Cross-sectional study where 78 patients admitted to Ain Shams University Quarantine hospitals with positive PCR for SARS-CoV-2 were enrolled. All patients underwent quantification of serum measles IgG titer. Then classified according to the COVID-19 severity into mild, moderate and severe. Results: Measles IgG was positive in 53 patients (68%) with median of 1600 (IQR 1000-or3100), borderline in 18 patients (23%) with median 250 (IQR 200-250) and negative in seven patients (9%) with median 100 (IQR 80-120). Patients with positive measles IgG were significantly older (56±16 years) than those with negative measles IgG ( 48±15 years) (P=0.03).No significant difference was found in measles IgG titer between mild , moderate and severe COVID19 cases. Intensity of pulmonary involvement by CT chest was not correlated with measles IgG titer. The median of measles IgG titer of the ICU admitted patients and those who were not, was 1150 (IQR=600-3500) and 1050 (IQR=200-1800) respectively (p=0.46). No difference in measles IgG titer between patients who recovered or died. Conclusion: Severity of COVID-19 disease and its outcome seem to be unaffected by measles IgG titer.
- 25 August 2021
- Published by Egyptian Knowledge Bank in Afro-Egyptian Journal of Infectious and Endemic Diseases
- Vol. 11 (3) , 306-313
Measles IgG Antibodies: Is There a Protective Role in COVID 19 Pandemic?
Background and study aim: Epidemiological data reported lower death rates of COVID-19 cases in countries with higher & recent coverage by measles containing vaccines. In this study we aim to identify measles IgG titer in COVID-19 patients & correlate it with disease severity. Patients and Method: This is a Cross-sectional study where 78 patients admitted to Ain Shams University Quarantine hospitals with positive PCR for SARS-CoV-2 were enrolled. All patients underwent quantification of serum measles IgG titer. Then classified according to the COVID-19 severity into mild, moderate and severe. Results: Measles IgG was positive in 53 patients (68%) with median of 1600 (IQR 1000-or3100), borderline in 18 patients (23%) with median 250 (IQR 200-250) and negative in seven patients (9%) with median 100 (IQR 80-120). Patients with positive measles IgG were significantly older (56±16 years) than those with negative measles IgG ( 48±15 years) (P=0.03).No significant difference was found in measles IgG titer between mild , moderate and severe COVID19 cases. Intensity of pulmonary involvement by CT chest was not correlated with measles IgG titer. The median of measles IgG titer of the ICU admitted patients and those who were not, was 1150 (IQR=600-3500) and 1050 (IQR=200-1800) respectively (p=0.46). No difference in measles IgG titer between patients who recovered or died. Conclusion: Severity of COVID-19 disease and its outcome seem to be unaffected by measles IgG titer.